Accountable for medical and scientific strategy. Lead the Global Medical Business Line including Medical, Medical Writing, Safety Pharmacovigilance, and Drug Development Consulting functions. Spearhead global expansion of Medical services into Europe and North America. Drive medical and scientific collaboration with our Biotech sponsors.

Provide advisory services to biopharmaceutical companies and academic researchers across all phases of company and therapeutic development including Clinical and Regulatory development strategy; Target Product Profile development; R & D organizational strategy; Staffing strategy including strategic outsourcing; and Program management/disciplined decision-making strategy. Sample client engagements include: - Academic investigators in various stages of progressing novel technologies into new companies.- Small to mid-size biotech repurposing clinical assets for new indications or therapeutic areas. - Biotech and Mid-size pharma developing indication and portfolio prioritization and strategy.- Small biotech building out Development team in preparation for regulatory submission and/or first in human studies.

Mentor and advise academic teams developing novel therapeutics with the goal of spinning out their inventions into biotech companies, leveraging product development and fund raising experience.

Provide Clinical Development and Regulatory Advice for the development of lead ADHD therapeutic intervention.

Served two 3 year termsFormer Board ChairPrevious Finance Committee MemberPrevious Executive Committee ChairPrevious Audit Committee Member

A private network designed for the most powerful women in executive leadership to strengthen their leadership, magnify their influence, and pave the way to bring others with them.

Accountable for the global research and development strategy and pipeline, pharmaceutical development strategy, safety and pharmacovigilance, regulatory strategy, and quality across pharmaceutical products in development and with market authorization. Represented the product development strategy to the Board of Directors and investment community. Managed the laboratory and pre-clinical development, clinical development, regulatory, safety, medical affairs, and pharmaceutical development teams. Achieved an ANDA approval and two successful pre-approval novel therapeutic in-licenses. Reported to the CEO.

Accountable for the research and development strategy and pipeline, manufacturing strategy and quality across the consumer and pharmaceutical products, and regulatory strategy. Represented the product development strategy to the Board of Directors and investment community. Deployed project management, risk management, and decision tools resulting in more rigorous decision making and team accountability. Managed the laboratory and pre-clinical development, clinical development, and manufacturing teams. Redesigned product development plan that resulted in positive Phase 2 clinical data. Reported to CEO.

Led the integration of the industry-recognized therapeutic and medical and scientific expertise within the enterprise and led collaboration with key medical and scientific stakeholders as the company partnered with clinicians, sponsor companies, and academic organizations. Drove the companywide focus on biotechnology, biosimilars, rare diseases and pediatrics through the specialized Consortia groups. Managed the global Safety and Pharmacovigilence organization of 1000 employees and $200 MM top line revenue. Reported to EVP, Head of Clinical Development.

Responsible for building | leading two outsourced service pillars within management consulting: Due Diligence (technical and regulatory probability of success and commercial value | market potential of proposed in-license candidates as well as comprehensive disease state entry opportunities, from competitive landscape analysis to reimbursement potential) and Medical Affairs (organizational review and recommendation of ideal structure, processes | procedures and governance framework.) Reported to SVP & Managing Director, Advisory Services.

Recruited into a new role to increase the visibility, impact, and value of physicians across the enterprise, as well as to strengthen the governance process across Phase I and clinical protocol development. Reported to Chief Medical and Scientific Officer.

Assumed new portfolio leadership role to accelerate integration into GSK and evolve its pharma R&D organization from life-cycle management to novel medicines development within Dermatology. Responsibilities included global acne and anti-infectives franchise strategy, clinical development strategy, regulatory and safety oversight, and R&D prioritization. Managed a team of 15 and a $30 million budget. Reported to Head of R&D.

Chosen to lead a new, risk management role in preparation for US Department of Justice integrity agreement, requiring a clear delineation between scientific exchange and product promotion. Scope include CNS, Cardiovascular, Metabolic, Infectious Disease, Dermatology, and Oncology. Reported to SVP, Projects, Clinical Platforms & Sciences.

Following an organizational restructuring and spin-off of the HIV unit, assumed responsibility for global infectious diseases portfolio that included clinical strategy, regulatory | safety issues, R&D activities, FDA submission and approval worldwide. Managed a total team of 70 and a $111 million budget. Reported to SVP, Global Head of Medicines Development.

Responsible for delivery of the infectious diseases clinical strategy, clinical development, medical and scientific marketing of products, North American medical affairs, the quality of clinical protocols, medical governance, and career development of clinical staff. Managed a team of 50. Reported to Global Head, Infectious Diseases Medicines Development Center.

Assumed responsibility for leading urgent RELENZA project to ensure timely fulfillment of post-approval commitments for inhaled zanamivir, including developing strategy for its lifecycle management. Directed the development of intravenous (IV) zanamivir. Led a matrix team of 15. Reported to VP, Discovery Medicine.